TargetBeta
CD4
CD4 molecule · also T4, Leu-3 · CD molecules
4 programs in company-led studies act on CD4, from 3 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| zamtocabtagene autoleucelrule | Miltenyi Biomedicine | phase 2 | 87 running | CD19, CD8A, MS4A1 | NCIt |
| TMB-365rule | TaiMed Biologics | phase 2 | 31 running | – | the studies' text |
| VRC07-523LSrule | TaiMed Biologics | phase 2 | 31 running | – | the studies' text |
| Allogeneic BAFF-L-expressing CAR T Cells LMY-922rule | Luminary Therapeutics | phase 1 | 22 running | – | NCIt |
Conditions their studies are in
- Arthritis, Rheumatoid, 1 program
- Lupus Nephritis, 1 program
- Lymphoma, B-Cell, 1 program
- Lymphoma, Large B-Cell, Diffuse, 1 program
- Lymphoma, Non-Hodgkin, 1 program
- Melanoma, 1 program
- Multiple Sclerosis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 31, 2026zamtocabtagene autoleucel · Miltenyi Biomedicine · phase 2 · NCT04792489
- May 2027TMB-365 · TaiMed Biologics · phase 2 · NCT07215468
- May 2027VRC07-523LS · TaiMed Biologics · phase 2 · NCT07215468
- Apr 2029Allogeneic BAFF-L-expressing CAR T Cells LMY-922 · Luminary Therapeutics · phase 1 · NCT07679919
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.